Immunological and classical subtypes of oral premalignant lesions

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86. doi:10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Divi V, Chen MM, Nussenbaum B, Rhoads KF, Sirjani DB, Holsinger FC, Shah JL, Hara W. Lymph node count from neck dissection predicts mortality in head and neck cancer. J Clin Oncol. 2016. doi:10.1200/JCO.2016.67.3863.
   PubMedGoogle Scholar
• Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350:1945–1952. doi:10.1056/NEJMoa032641.
   PubMed Web of Science ®Google Scholar
• Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med. 2016; 45: 155–166. doi:10.1111/jop.12339.
   PubMed Web of Science ®Google Scholar
• Balasundaram I, Payne KF, Al-Hadad I, Alibhai M, Thomas S, Bhandari R. Is there any benefit in surgery for potentially malignant disorders of the oral cavity? J Oral Pathol Med. 2014; 43: 239–244. doi:10.1111/jop.12088.
   PubMed Web of Science ®Google Scholar
• Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S. Hittelman W, Hong WK. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996;2:682–685.
   PubMed Web of Science ®Google Scholar
• Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–362.
   PubMed Web of Science ®Google Scholar
• Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, Jiang H, Wu L, Lee JJ, Rosin MP. Loss of heterozygosity (LOH) profiles–validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila). 2012; 5:1081–1089. doi:10.1158/1940-6207.CAPR-12-0173.
   PubMed Web of Science ®Google Scholar
• Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Wenhua Lang, You-Hong Fan, Jiannan Huang, Lei Feng, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010; 3:800–809. doi:10.1158/1940-6207.CAPR-09-0163.
   PubMed Web of Science ®Google Scholar
• Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011; 4:230–237. doi:10.1158/1940-6207.CAPR-10-0249.
   PubMed Web of Science ®Google Scholar
• Bauman JE, Grandis J. Oral Cancer Chemoprevention–the End of EPOC, the beginning of an epoch of molecular selection. JAMA Oncol. 2016; 2: 178–179. doi:10.1001/jamaoncol.2015.4637.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, William WN, Jr., Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008; 14:2095–2101. doi:10.1158/1078-0432.CCR-07-4024.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Lee JJ, William WN, Jr., Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009; 27:599–604. doi:10.1200/JCO.2008.17.1850.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993; 328:15–20. doi:10.1056/NEJM199301073280103.
   PubMed Web of Science ®Google Scholar
• William WN, Jr., Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, et al. Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol. 2016; 2:209–216. doi:10.1001/jamaoncol.2015.4364.
   PubMed Web of Science ®Google Scholar
• Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986; 315:1501–1505. doi:10.1056/NEJM198612113152401.
   PubMed Web of Science ®Google Scholar
• Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, et al. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013; 6:410–418. doi:10.1158/1940-6207.CAPR-13-0004.
   PubMed Web of Science ®Google Scholar
• Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, Ang MK, Hayward MC, Salazar AH, Hoadley KA, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013; 8:e56823. doi:10.1371/journal.pone.0056823.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517: 576–582. doi:10.1038/nature14129.
   PubMed Web of Science ®Google Scholar
• Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M. Rieke D, Endhardt K, Fang P, Brägelmann J, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015; 21:870–881. doi:10.1158/1078-0432.CCR-14-2481.
   PubMed Web of Science ®Google Scholar
• De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, Locati L, Licitra L, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: meta-analysis of gene-expression data. Oncotarget. 2015; 6:9627–9642. doi:10.18632/oncotarget.3301.
   PubMed Web of Science ®Google Scholar
• Foy JP, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, Viari A, Puisieux A, Goudot P, Bertolus C, et al. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med. 2017; 15:165. doi:10.1186/s12916-017-0929-y.
   PubMed Web of Science ®Google Scholar
• Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011; 4:218–229. doi:10.1158/1940-6207.CAPR-10-0155.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462:108–112. doi:10.1038/nature08460.
   PubMed Web of Science ®Google Scholar
• Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006; 38: 500–501. doi:10.1038/ng0506-500.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17:218. doi:10.1186/s13059-016-1070-5.
   PubMed Web of Science ®Google Scholar
• Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009; 15:6284–6291. doi:10.1158/1078-0432.CCR-09-0498.
   PubMed Web of Science ®Google Scholar
• Tsitsiou E, Lindsay MA. microRNAs and the immune response. Curr Opin Pharmacol. 2009; 9: 514–520. doi:10.1016/j.coph.2009.05.003.
   PubMed Web of Science ®Google Scholar
• El Gazzar M, McCall CE. MicroRNAs regulatory networks in myeloid lineage development and differentiation: regulators of the regulators. Immunol Cell Biol. 2012; 90: 587–593. doi:10.1038/icb.2011.74.
   PubMed Web of Science ®Google Scholar
• Podshivalova K, Salomon DR. MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development. Crit Rev Immunol. 2013;33:435–476.
   PubMed Web of Science ®Google Scholar
• Rosin MP, Lam WL, Poh C, Le ND, Li RJ, Zeng T, Priddy R, Zhang L. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 2002;62:6447–6450.
   PubMed Web of Science ®Google Scholar
• Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, et al. Precancer atlas to drive precision prevention trials. Cancer Res. 2017; 77:1510–1541. doi:10.1158/0008-5472.CAN-16-2346.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CRMuldrew K, Miller CR, Randell SH, Socinski MA, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res. 2010; 16:4864–4875. doi:10.1158/1078-0432.CCR-10-0199.
   PubMed Web of Science ®Google Scholar
• Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011; 17:1490–1501. doi:10.1158/1078-0432.CCR-10-2703.
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, pan-cancer emt signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016; 22:609–620. doi:10.1158/1078-0432.CCR-15-0876.
   PubMed Web of Science ®Google Scholar
• Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017; 171:1611–24 e24. doi:10.1016/j.cell.2017.10.044.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2018; 48:812–30 e14. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, Pintilie M, Jurisica I, Perez-Ordonez B, Gilbert R, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet. 2009; 18:4818–4829. doi:10.1093/hmg/ddp446.
   PubMed Web of Science ®Google Scholar
• Su S, Zhao Q, He C, Huang D, Liu J, Chen F, Chen J, Liao JY, Cui X, Zeng Y, et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun. 2015; 6:8523. doi:10.1038/ncomms9523.
   PubMed Web of Science ®Google Scholar
• Xu S, Wei J, Wang F, Kong Ly, Ling Xy, Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, et al. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014:106(8). pii: dju162. doi:10.1093/jnci/dju162.
   Google Scholar
• Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, et al. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A. 2016; 113:10750–10758. doi:10.1073/pnas.1608077113.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra LHarrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016. doi:10.1200/JCO.2016.68.1478.
   Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016. doi:10.1016/S1470-2045(16)30066-3.
   PubMedGoogle Scholar
• Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol. 2017; 45: 52–59. doi:10.1016/j.coi.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Woodford D, Johnson SD, De Costa AM, Young MR. An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol. 2014;5(3). pii: 230.
   Google Scholar
• Yagyuu T, Hatakeyama K, Imada M, Kurihara M, Matsusue Y, Yamamoto K, Obayashi C, Kirita T. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: implications for patients with oral precancerous lesions. Oral Oncol. 2017; 68:36–43. doi:10.1016/j.oraloncology.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006; 12:465–472. doi:10.1158/1078-0432.CCR-05-1886.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016; 38:1074–1084. doi:10.1002/hed.24406.
   PubMed Web of Science ®Google Scholar
• Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rodel F, Rödel C, Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014; 110:501–509. doi:10.1038/bjc.2013.640.
   PubMed Web of Science ®Google Scholar
• Foy JP, Tortereau A, Caulin C, Le Texier V, Lavergne E, Thomas E, Chabaud S, Perol D, Lachuer J, Lang W, et al. The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. Oncotarget. 2016. doi:10.18632/oncotarget.8321.
   Google Scholar
• Johnson SD, Levingston C, Young MR. Premalignant oral lesion cells elicit increased cytokine production and activation of T-cells. Anticancer Res. 2016;36:3261–3270.
   PubMed Web of Science ®Google Scholar
• Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015; 112: 1809–1814. doi:10.1073/pnas.1417636112.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26: 1572–1573. doi:10.1093/bioinformatics/btq170.
   PubMed Web of Science ®Google Scholar
• Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015; 12:115–121. doi:10.1038/nmeth.3252.
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4:249–264. doi:10.1093/biostatistics/4.2.249.
   PubMed Web of Science ®Google Scholar
• Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33:e175. doi:10.1093/nar/gni179.
   PubMed Web of Science ®Google Scholar
• Fan Y, Siklenka K, Arora SK, Ribeiro P, Kimmins S, Xia J. miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis. Nucleic Acids Res. 2016; 44: W135–41. doi:10.1093/nar/gkw288.
   PubMed Web of Science ®Google Scholar
• Jacomy M, Venturini T, Heymann S, Bastian M. ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. PLoS One. 2014 Jun 10;9(6):e98679. doi:10.1371/journal.pone.0098679. eCollection 2014. PMID: 24914678
   Google Scholar